AUTH/3663/6/22 - Complainant v Roche

Allegations about the promotion of Ocrevus on the Roche resources website

  • Received
    19 June 2022
  • Case number
  • Applicable Code year
  • Completed
    14 June 2023
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to allegations that Ocrevus (ocrelizumab) had been promoted for unlicensed indications on the congress and meetings landing page on the Roche resources website.

The Panel ruled no breach of the following Clauses of the 2021 Code, as it did not consider that the complainant had established that:

• the congress and meetings landing page advertised prescription only medicines to the public,
• reference to COVID-19 in a meeting title ‘COVID-19 in Ocrevus-treated patients – the story so far’ was misleading or implied that Ocrevus was indicated for COVID-19, and
• the inclusion of a link to the Ocrevus prescribing information on the webpage, in itself, would imply to a health professional that the medicine was licensed for all the conditions and therapeutic areas mentioned within the congress/meeting tiles on that page.

No Breach of Clause 2

Requirement that material must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 3.2

Requirement not to advertise prescription only medicines to the public

No Breach of Clause 5.1

Requirement to maintain high standards

No Breach of Clause 11.2

Requirement not to promote a medicine for an unlicensed indication

This summary is not intended to be read in isolation.
For full details, please see the full case report below.